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Journal of the American Heart Association
BRIEF COMMUNICATION

Associations Between Atrial Cardiopathy
and Cerebral Amyloid: The ARIC-PET Study
Michelle C. Johansen, MD, PhD ; Thomas H. Mosley , PhD; David S. Knopman , MD; Dean F. Wong, MD, PhD;
Chiadi Ndumele, MD; Amil M. Shah , MD; Scott D. Solomon, MD; Rebecca F. Gottesman , MD, PhD
BACKGROUND: Atrial fibrillation (AF) is a risk factor for cognitive decline, possibly from silent brain infarction. Left atrial changes
in structure or function (atrial cardiopathy) can lead to AF but may impact cognition independently. It is unknown if AF or atrial
cardiopathy also acts on Alzheimer disease–specific mechanisms, such as deposition of β-amyloid.
METHODS AND RESULTS: A total of 316 dementia-free participants from the ARIC (Atherosclerosis Risk in Communities) study
underwent florbetapir positron emission tomography, electrocardiography, and 2-dimensional echocardiography. Atrial cardiopathy was defined as ≥1: (1) left atrial volume index >34 mL/m2; (2) P-wave terminal force >5000 µV×ms; and (3) serum
NT-proBNP (N-terminal pro-B-type natriuretic peptide) >250 pg/mL. Cross-sectional associations between global cortical
β-amyloid (>1.2 standardized uptake value ratio) and adjudicated history of AF and atrial cardiopathy, each, were evaluated
using multivariable logistic regression. Participants (mean age, 76 years) were 56% women and 42% Black individuals. Odds
of elevated florbetapir standardized uptake value ratio were significantly increased among those with atrial cardiopathy (odds
ratio, 1.81; 95% CI, 1.02–3.22) and doubled for those with enlarged left atrial volume index after adjustment for demographics/risk factors (95% CI, 1.04–4.61). There was no association between P-wave terminal force or NT-proBNP and elevated
florbetapir standardized uptake value ratio, nor between AF and elevated standardized uptake value ratio.
Downloaded from http://ahajournals.org by on February 1, 2022

CONCLUSIONS: Among healthy, nondemented community-dwelling older individuals, we report an association between atrial
cardiopathy, left atrial volume index, and elevated brain amyloid, by positron emission tomography, without a similar association in individuals with AF. Potential limitations include reverse causation and survival bias. Ongoing work will help determine if
changes in cardiac structure and function precede or occur simultaneously with amyloid deposition.
Key Words: atrial cardiopathy ■ cognitive decline ■ cohort study ■ positron emission tomography

P

oststroke cognitive decline and dementia represent a significant public health problem.1,2 There
have been several reasons postulated as the
cause of poststroke cognitive decline, but the precise
mechanisms remain unclear. Patients with cardioembolic stroke in particular are at increased risk for cognitive decline compared with other stroke subtypes.3
Atrial fibrillation (AF), the most common cause of cardioembolic stroke, has been suggested as the potential
driver in this association. However, growing literature
suggests that the paradigm of AF as the only pathway
leading to cardioembolic stroke is not sufficient, with
patients with implantable cardiac devices, for example,

sometimes showing no relationship between the timing of AF and the stroke event.4,5 A newer model now
suggests AF is only one mechanism by which embolization from the left atrium (LA) can occur.6 A state
of atrial cardiopathy, or dysfunction of the LA, has
been defined in different ways, but the overarching
goal is to capture the potentially causative, pathophysiologic changes that lead to thromboembolism.
The ARCADIA (Atrial Cardiopathy and Antithrombotic
Drugs in Prevention After Cryptogenic Stroke) trial is
one example of an ongoing secondary stroke prevention trial that uses a biomarker-driven approach to define LA dysfunction, randomizing patients to different
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medications (antiplatelet versus anticoagulation) based
on the presence of atrial cardiopathy.7 We have previously demonstrated that subclinical changes in left
ventricle structure and function were associated with
increased brain β-amyloid deposition.8 The aim of this
study is to determine if the presence of atrial cardiopathy, defined using a definition similar to ARCADIA trial,
was associated with the presence of aggregated brain
β-amyloid in a cohort of older adults without dementia,
independent of underlying vascular risk.

METHODS
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The study was approved by the Institutional Review
Board at all institutions involved, and informed consent
was obtained. Data that support the findings of this
study are available per ARIC (Atherosclerosis Risk in
Communities) study policies.
The ARIC study is a community-based cohort
study whose methods have been described in detail
elsewhere.9 In addition to the parent ARIC study, the
ARIC Neurocognitive study enrolled patients for detailed cognitive assessments and magnetic resonance
imaging, of whom 346 nondemented individuals were
recruited to undergo florbetapir positron emission tomography (PET) (amyloid) imaging, in the ARIC-PET
ancillary study.10 Participants also had transthoracic
echocardiography, cardiac monitoring, and venipuncture, as has been previously described.11 The cardiac
assessment occurred before, but <1 year, from PET.
Individuals in the ARIC-PET study who were missing
exposure data or covariates were excluded from this
analysis (Figure).

Atrial Cardiopathy
Atrial cardiopathy for this study was defined using 3 different biomarkers, capturing different aspects of LA function. It required ≥1 of the following: P-wave terminal force
>5000 μV×ms in ECG lead V1, serum amino terminal
NT-proBNP (N-terminal pro-B-type natriuretic peptide)
>250 pg/mL, and LA volume index (LAVI) ≥34 mL/m2,
per established guidelines.12 P-wave terminal force was
calculated by multiplying amplitude by duration from
participant ECG. LAVI was specifically chosen instead of
more frequently reported LA diameter (criteria used for
ARCADIA trial), as data support this measure as superior for LA remodeling.13 Participants were not required
to have AF to meet criteria for atrial cardiopathy.

Brain Imaging
Florbetapir PET was conducted at the 3 enrolling
sites with standardization performed to ensure effectively equivalent spatial resolution of 8.30 mm
for the 3 sites. Radioisotope (florbetapir) was administered with a butterfly needle for the 20-minute
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(4×5 minutes) uptake scan, with image acquisition
between 50 and 70 minutes. The Johns Hopkins
University Department of Radiology, Section of
High-Resolution Brain PET imaging core, reviewed
all scans for image quality and conducted measurements of standardized uptake value ratios (SUVRs),
as has been previously reported. The primary unit for
analysis was a weighted average of 9 brain regions
(orbitofrontal, prefrontal, superior frontal cortices,
lateral temporal, parietal and occipital lobes, precuneus, and anterior and posterior cingulates), which
were used to define a global cortical measure of aggregated β-amyloid. Elevated florbetapir was defined
as SUVR >1.2, the sample median, because of the
highly skewed distribution of the data.

Covariate Assessment
Covariates were defined on the basis of participant
status at the time of the fifth study visit, with the exception of race, sex, and education level, which were
defined at ARIC study baseline. Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or antihypertensive
medication use. Diabetes mellitus was defined as a
hemoglobin A1C ≥6.5%. Low-density lipoprotein was
analyzed continuously (mg/dL), as was body mass
index (kg/m2) and estimated glomerular filtration rate
(mL/min per 1.73 m2). Race was self-reported (Black or
White race), as were smoking status and level of educational attainment. Smoking status was considered a
binary variable, either having ever smoked cigarettes
(ever smoker) versus never smoking. The 3 potential
responses for education level were less than high
school, graduation from high school or general educational development equivalent, or education beyond
high school (college or graduate work). Coronary heart
disease was defined as prevalent before visit 5 and
was a binary variable. Prevalent AF was considered to
be present if AF was diagnosed at any ARIC study visit
preceding and including visit 5, concurrent with brain
magnetic resonance imaging. AF diagnosis was based
on the following criteria: standard ECG or presence of
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM), code 427.3x in the
absence of open heart surgery in any prior hospitalization. Apolipoprotein E (APOE) alleles were considered
for participants who gave consent for genetic data
use, with alleles collapsed into a binary variable for the
presence or absence of at least one APOE e4 allele.

Statistical Analysis
For continuous variables, means and SDs are reported; and for categorical variables, frequencies
are reported. Multivariable logistic regression modeled the association of cerebral amyloid (SUVR >1.2),
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with (1) each LA variable, (2) atrial cardiopathy, and
(3) prevalent AF, separately, adjusted for confounders in stepwise models, with interaction terms for
sex and race when appropriate. Model 1 adjusts for
age, race, sex, education level, hypertension, diabetes mellitus, low-density lipoprotein, smoking history,
body mass index, coronary heart disease, and estimated glomerular filtration rate. Model 2 adjusts for
model 1 and prevalent AF. Model 3 adjusts for model
2, APOE e4 allele, and mild cognitive impairment
(MCI). AF was excluded from the adjustment model
when it was considered as an independent variable.
Sensitivity analyses assessed for effect measure
modification by APOE e4 allele and cognitive status, rather than adjusting for them as covariates.
Covariates were chosen on the basis of associations
in the literature, and were believed to potentially confound the relationship between LA function and cerebral amyloid.

RESULTS
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A total of 316 participants met inclusion criteria
(311 permitted APOE e4 use) and were aged 70 to
82 years, 56% were women, and 42% were Black
individuals. Seventeen participants had prevalent
AF, 98 met criteria for atrial cardiopathy, and 88 had
MCI (Table 1). Demographics were also stratified by
cognitive status, with no statistically significant differences between those with MCI and those cognitively normal (Table S1). Black participants were more
likely to be hypertensive and have higher body mass
index, low-density lipoprotein, and estimated glomerular filtration rate than White participants (details
not shown).10
There was approximately 2 times the odds of elevated florbetapir SUVR among those participants
with an LAVI ≥34 mL/m2, with the effect estimate
becoming larger and statistically significant after
adjustment for AF, APOE e4, and MCI (95% CI,
1.04–4.61; model 3; Table 2), but no association was
found among participants with an elevated P-wave
terminal force (N=21) or elevated serum NT-proBNP
(N=61). Prevalent AF (N=17), as an independent variable, was not associated with florbetapir SUVR >1.2.
Among those with atrial cardiopathy, there were increased odds of florbetapir SUVR >1.2 in the more
fully adjusted model, including APOE e4 and MCI
(odds ratio [OR], 1.81; 95% CI, 1.02–3.22; model 3).
There was no evidence of effect measure modification by APOE e4 (e4 allele OR, 1.43; no e4 allele OR,
2.03; P-interaction=0.81), race (P-interaction=0.86),
or sex (P-interaction=0.52) when considering the relationship between atrial cardiopathy and elevated
florbetapir SUVR (details not shown). Relationships
between cardiac markers and amyloid were similar

Atrial Cardiopathy and Cerebral Amyloid

Table 1. Participant Demographics (N=316)
Characteristic
Age, mean (SD), y
Women

Value
76 (5)
177 (56)

Black race

135 (42)

History of ever smoking

182 (58)

Hypertension

233 (74)

Low-density lipoprotein, mean (SD), mg/dL

106 (33)

Diabetes mellitus

108 (34)

Body mass index, mean (SD), kg/m2

29 (5)

Prevalent coronary heart disease

25 (8)

Estimated glomerular filtration rate, mean
(SD), mL/min per 1.73 m2

71 (17)

Education level
Less than high school

51 (16)

High school graduate or equivalent

135 (43)

More than high school

130 (41)

Prevalent atrial fibrillation

17 (5)

APOE e4

98 (32)

Mild cognitive impairment

88 (27)

Values are number (percentage) unless otherwise specified; hypertension
was defined as systolic blood pressure ≥140 mm Hg, diastolic blood
pressure ≥90 mm Hg, or antihypertensive medication use; diabetes mellitus
was defined as a hemoglobin A1C ≥6.5%. APOE indicates apolipoprotein E.

in the cognitively normal and MCI groups, without
evidence of effect modification by cognitive status,
although with loss of power because of smaller numbers (Table S2).

DISCUSSION
In this cross-sectional analysis of a cohort of healthy,
nondemented community-dwelling older individuals,
we report a significant association between (1) LAVI
and (2) atrial cardiopathy, defined using 3 different
aspects of LA function, similarly to an ongoing clinical trial, and elevated PET florbetapir SUVR, an imaging marker for amyloid, when accounting for APOE
e4 carriage and cognitive status. We recognize that
there are limitations to this analysis. Cases of AF may
have been missed, as diagnosis was based on inclinic ECG data or adjudicated events from hospitalizations only. There is the possibility for reverse
causation (because of the cross-sectional nature
of the study) and survival bias. Although our results
were robust to adjustment for potential confounders, we acknowledge the potential for unmeasured
confounding. However, this work is novel in that our
findings raise the possibility that cardiac disease in
the form of a state of atrial cardiopathy, and the cellular pathological features that underlie it, may (directly or indirectly) impair brain integrity. This may
lead to later life cognitive impairment through a brain
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Table 2. Odds of Elevated Global Cortical Cerebral Amyloid by Florbetapir PET (SUVR >1.2) by Cardiac Variable (N=316)
Model 1
Cardiac Independent
Variable

Model 2

Model 3

No. With Specified
Cardiac Variable

OR

95% CI

OR

95% CI

OR

95% CI

LAVI ≥34 mL/m2

50

1.87

0.93–3.58

2.11

1.03–4.31

2.18

1.04–4.61

P-wave terminal force
>5000 μV×ms

21

0.85

0.33–2.19

0.88

0.34–2.29

0.79

0.29–2.14

Serum NT-proBNP
>250 pg/mL

61

1.65

0.86–3.16

1.83

0.93–3.61

2.00

0.97–4.12

Atrial cardiopathy

98

1.55

0.92–2.62

1.70

0.98–2.92

1.81

1.02–3.22

Prevalent atrial fibrillation

17

0.65

0.23–1.87

N/A

N/A

0.73

0.24–2.17

Adjustment models: model 1=age, race (Black or White race), sex, education level (less than high school, high school graduation/equivalent, or more than
high school), hypertension (systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or antihypertensive medication use), diabetes mellitus
(hemoglobin A1C ≥6.5%), low-density lipoprotein (mg/dL), smoking history (ever vs never), body mass index (kg/m2), prevalent coronary heart disease, and
estimated glomerular filtration rate (mL/min per 1.73 m2). Model 2=model 1+prevalent atrial fibrillation. Model 3=model 2+apolipoprotein e4 and mild cognitive
impairment (311 permitted apolipoprotein e4 use, so smaller sample). LAVI indicates left atrial volume index; N/A, nonapplicable; NT-proBNP, N-terminal proB-type natriuretic peptide; OR, odds ratio; PET, positron emission tomography; and SUVR, standardized uptake value ratio.
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β-amyloidogenic mechanism in addition to, or even
as a consequence of, cardioembolism and subsequent brain infarction.
LA enlargement, measured in our study using LAVI,
which represents a structural biomarker of LA function,
might lead to brain amyloid deposition through either
changes in perfusion or promoting embolism. LA enlargement has been associated with AF, but the directionality of a potential cause-effect relationship has not
been established. There may be a multihit phenomenon,
with literature suggesting that in patients with Alzheimer
disease, those with the APOE e4 allele and permanent
AF have lower Mini-Mental State Examination scores
and the highest risk of cognitive deterioration when
compared with similar individuals without AF.14

346

Initial ARIC-PET cohort

343

•Demented (1)
•Race other than black or white (2)

330

•LA volume index missing (3)
•P wave on ECG not captured (3)
•NT-proBNP missing (7)

316

•Participants missing ≥1 covariate (14)

A state of atrial cardiopathy is increasingly recognized
as an important impetus for thrombi, and subsequent
embolism, even without the development of AF. We
therefore cautiously suggest that an earlier diagnosis of
LA dysfunction, using a compilation of biomarkers, such
as atrial size, measured herein by LAVI, may identify a
cohort at risk for a pathologic precursor of Alzheimer disease. Further research into this question in ARIC study
is ongoing, with recent data suggesting that participants
with LA enlargement and AF had significantly lower
global cognition, whereas those with AF or LA enlargement alone did not, compared with individuals with normal LA size and no AF.15
We certainly do not imply causality, and importantly
acknowledge that although no significant interaction
term, the role of APOE e4 carriage is thought provoking,
suggesting atrial cardiopathy may be more important for
noncarriers. In addition, although the data for cerebral
amyloidosis are robust, there is currently insufficient evidence to support its involvement in an atrial cardiopathy.
Important ongoing work will help determine if
changes in cardiac structure and function precede, or
occur simultaneously with, brain amyloid deposition.
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Table S1. Participant demographics, stratified by cognitive status* (N=316).
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Cognitive Status
Mild cognitive impairment (N=85) Cognitively normal (N=231)
P-value
Age (years old), mean (SD)
76 (5)
77 (5)
0.08
Female
135 (58)
42 (49)
0.15
Black race
99 (43)
36 (42)
0.94
History of ever smoking
134 (58)
48 (57)
0.81
Hypertension
167 (72)
66 (78)
0.34
Low density lipoprotein (mg/dL), mean (SD) 107 (33)
102 (31)
0.26
Diabetes
72 (31)
36 (42)
0.06
Body mass index (kg/m2), mean (SD)
29 (5)
29 (5)
0.88
Prevalent coronary heart disease
20 (9)
5 (6)
0.42
Estimated glomerular filtration rate
71 (17)
71 (18)
0.92
(mL/min/1.73 m2), mean (SD)
Education level
<High School
35 (15)
16 (19%)
0.73
High School Graduate or equivalent
100 (43)
35 (41%)
>High school
96 (41)
34 (40)
Prevalent atrial fibrillation
13 (6%)
4 (5%)
0.75
APOE e4
66 (29)
32 (38%)
0.13
* Values are N (%) unless otherwise specified; Hypertension was defined as systolic blood pressure ≥140, diastolic blood pressure
≤90 or antihypertensive medication use, Diabetes was defined as a hemoglobin A1C ≥6.5%

Table S2. Odds of elevated global cortical cerebral amyloid by florbetapir PET (SUVR>1.2) by cardiac variable, stratified by
cognitive status (participants with dementia ineligible).
Cognitively normal
MCI (N=81)
(N=233)

Cardiac Independent Variable

P-interaction term

OR

95% CI

OR

95% CI

LAVI (ml/m2) ≥34 ml/m2

8.36

0.88-79.66

1.77

0.77-4.05

0.26

P-wave terminal force >5000 uV x ms

1.96

0.14-27.11

0.55

0.16-1.90

0.44

serum NT proBNP>250 pg/mL

0.81

0.19-3.52

2.77

1.15-6.65

0.43

Atrial Cardiopathy

2.04

0.51-8.18

1.77

0.98-3.37

0.26
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Prevalent Atrial fibrillation
0.55
0.15-2.01
3.44
0.21-57.36
MCI=mild cognitive impairment, LAVI=left atrial volume index, OR=odds ratio, CI=confidence interval

0.31

Adjustment model: age, race (black or white), sex, education level (<high school, high school graduation/equivalent, >high school),
hypertension (systolic blood pressure ≥140mm Hg, diastolic blood pressure ≥90mm Hg or antihypertensive medication use), diabetes
mellitus (hemoglobin A1C ≥6.5%), low density lipoprotein (mg/dL), smoking history (ever versus never), body mass index (kg/m2),
prevalent coronary heart disease, estimated glomerular filtration rate-creatinine (mL/min/1.73 m2), prevalent atrial fibrillation, APOE
e4

